QUALITY OF LIFE AND ADHERENCE TO THERAPY IN PATIENT WITH RHEUMATOID ARTHRITIS
Relevance: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to progressive joint damage and systemic complications. It significantly reduces patients' quality of life (QoL), affecting their physical, psychological, and social well-being. Assessing QoL is a crucial criterion for evaluating treatment effectiveness and requires the use of specialized instruments and questionnaires. This study aims to assess changes in QoL and treatment adherence among RA patients over one year of baseline therapy using the SF-36 and HAQ questionnaires.
Materials and Methods: A prospective observational study was conducted on 109 patients with a confirmed RA diagnosis (ACR/EULAR 2010 criteria). Enrollment took place in 2021, with reassessment after 12 months. Clinical parameters (DAS28, VAS), QoL measures (SF-36, HAQ), and treatment adherence (Morisky-Green questionnaire) were evaluated. Data analysis was performed using SPSS 26.0.
Results: The mean age of the patients was 56.3 years, with 77% being women. After one year of therapy, a statistically significant improvement in QoL was observed: the physical component of SF-36 (PCS) increased by 8.3 points, and the psychological component (MCS) increased by 10.6 points (p < 0.001). The HAQ index decreased by 0.4 points, indicating improved functional status. However, only 59.6% of patients demonstrated high adherence to treatment, while 40.4% had low adherence, which correlated with poorer QoL scores and higher disease activity.
Conclusions: High treatment adherence positively influences QoL and disease activity in RA patients. Additional strategies, including digital technologies, counseling, and personalized treatment approaches, are necessary to enhance adherence and optimize patient outcomes.
Petrova Yuliya Viktorovna – Master of Medicine, Department of Internal Medicine and Rheumatology NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; Email: yuliya.petrova@smu.edu.kz; phone number: +7(771) 537 6060; https://orcid.org/0000-0003-1910-7169
Ivanova Raifa Latyfovna– Professor, Doctor of Medical Sciences, Department of Internal Medicine and Rheumatology NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; Email: raifa.ivanova@smu.edu.kz; phone number: +7(777)147 2892; https://orcid.org/0000-0001-9851-2255
Goremykina Maya Valentinovna - Candidate of Medical Sciences, Associate Professor, Department of Internal Medicine and Rheumatology, NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; Email: maya.goremykina@smu.edu.kz; phone number: +7 (777) 390 8234; https://orcid.org/0000-0002-5433-7771
Serikova Talshyn Kairgalievna - Resident of 2 years of training in the specialty “Rheumatology adult and pediatric”, NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; Email: talshyn.sk@gmail.com; phone number: +7(747) 184 4363; https://orcid.org/0009-0009-6840-1066
Karakanova Aigerim Baurzhankyzy - Resident of 2 years of training in the specialty “Rheumatology adult and pediatric”, NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; Email: moldabaevaa098@gmail.com; phone number: +7(707) 655 2814 https://orcid.org/0009-0008-2218-9082
Bakytova Anel Baqtiyarkyzy - Resident of 2 years of training in the specialty “Rheumatology adult and pediatric”, NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; phone number: +7(777) 375 3675; https://orcid.org/0009-0007-8804-4313
Seitkhan Danura Seytkhankyzy - Resident of 2 years of training in the specialty “Rheumatology adult and pediatric”, NJSC «Semey Medical University», 103 Abay street, Semey, 071400, Kazakhstan; Email: danuraseithan9@gmail.com; phone number: +7(707) 372 0895; https://orcid.org/0009-0001-7447-8889
Nogayeva Maral Gazizovna – Candidate of Medical Sciences, Professor of the Department of Rheumatology, Kazakh National Medical University named after S.D. Asfendiyarov, e-mail: maral.nogaeva@xmail.ru, Almaty, +7 708 800 52 65; https://orcid.org/0000-0003-1182-5967
1. Амирджанова В.Н., Койлубаева Г.М., Горячев Д.В., Фоломеева О.М., Эрдес Ш.Ф. Валидация русскоязычной версии Health Assessment Questionnaire (HAQ). Научно-практическая ревматология. 2004. №2. С. 69-76
2. Клинические протоколы МЗ РК - 2016 (Казахстан). Ревматоидный артрит. Availablefrom: https://diseases.medelement.com/
3. Котовская М.А., Никишина Н.Ю., Олюнин Ю.А. Персонализированная медицина: предикторы эффективности терапии биологическими агентами при ревматоидном артрите. Modern Rheumatology Journal. 2017. 11(2). С. 4-17
4. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008, 290-331.
5. Полищук Е.Ю., Каратеев А. Е., Потапова А. С., Филатова Е., Хлабощина В.Н., Амирджанова В.Н., Лила А.М. Нужно ли оценивать эффект терапии? Спросите пациента! Научно-Практическая Ревматология; 2023; 61(3): 361–368.
6. Эрдес Ш., Эрдес К.Ш. Вопросник SF-36 и использование его при ревматоидном артрите. Научно-практическая ревматология: 2003. №2. С. 47-52
7. Brahem M., Sarraj R., Jebali B. et al. Factors affecting quality of life in patients with rheumatoid arthritis // Annals of the Rheumatic Diseases. 2023. Т. 82, Suppl 1, 1321–1321
8. Feki A., Sellami I., Mnif I., Gassara Z. et al. Quality of Life Assessment in Female Rheumatoid Arthritis Patients. European Psychiatry. 2024. Т. 67, Suppl 1, S809–S810.
9. Feng J., Yu L., Fang Y., Zhang X., Li S., Dou L. Correlation between disease activity and patient-reported health-related quality of life in rheumatoid arthritis: a cross-sectional study. BMJ Open. 2024. Т. 14. рp.1-8
10. Fransen J., van Riel P.L.The Disease Activity Score and the EULAR responsecriteria. Rheumatic Disease Clinics of North America. 2009. Т. 35, №4, p.745-755.
11. Haridoss M., Bagepally B.S., Natarajan M. Health-related quality of life in rheumatoidarthritis: Systematic review and meta-analysis ofEuroQoL (EQ-5D) utility scores from Asia. International Journal of Rheumatic Diseases. 2021. Т. 24, №3, рр.314–326.
12. Knight E., Carluzzo K. L., Reeve B.B. et al. Health-related quality of life profiles of adults with arthritis and/or fibromyalgia: a cross-sectional study. Quality of Life Research. 2024. 34(2). p.523-534
13. Lau C., Chia F., Harrison A. et al. APLAR rheumatoid arthritis treatment recommendations. International Journal of Rheumatic Diseases. 2015. Т. 18 p.685–713.
14. Lillegraven S., Kvien T.K. Measuring disability and quality of life in established rheumatoid arthritis. Best Practice & Research Clinical Rheumatology. 2007. Т. 21, №5, p.827–840
15. Maska L., Anderson J., Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken). 2011. Т. 63, Suppl 11. p.4-13.
16. Matcham F., Scott I.C., Rayner L. et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014. Т. 44, №2. p. 123-130.
17. McGonagle D., Watad A., Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmunity Reviews. 2018. Т. 17, №11. p. 1115–1123.
18. Rodríguez-Montero S., Velloso-Feijoó M.L., Almeida C. Biological therapy optimization in patients with moderate to severe rheumatoid arthritis: Analysis of effectiveness in a cohort of patients in clinical practice conditions. Annals of the Rheumatic Diseases. 2024. рp.1558 – 1559.
19. Sakai R., Tanaka E., Inoue E., Sato M., Tanaka M., Ikari K., Yamanaka H., Harigai M. Subjective Symptoms Contributing to the Quality of Life of Rheumatoid Arthritis Patients with Clinical Remission from the IORRA Database. Modern Rheumatology. 2022. №33 (3). p.496-502
20. Santiago-Garcia A.P., Gamez-Nava J.I., Avalos-Salgado F.A. et al. Research Group for Factors Related to Therapeutic Outcomes in Autoimmune Diseases. Complementary Therapies and Their Association with Problems in Therapeutic Adherence to Conventional Synthetic DMARDs in Rheumatoid Arthritis: A Cross-Sectional Study. Healthcare (Basel). 2023. Т.12, №1. p. 49.
21. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016. Т. 388, №10055. p. 2023-2038.
22. Song Y., Chen Y., Wen L. et al. Health-related quality of life profiles in patients with rheumatoid arthritis: a latent profile analysis. Frontiers in Public Health. 2024. Т. 12. p.2296-2565.
23. Tanski W., Dudek K., &Adamowski T. Work Ability and Quality of Life in Patients with Rheumatoid Arthritis. International Journal of Environmental Research and Public Health, 2022. 19(20) p.13260
24. Van den Hoek J., Boshuizen H.C., Roorda L.D., et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatology International.2017. Т. 37, №4, p.487–493.
25. Wei M., Chu C.Q. Prediction of treatment response: Personalized medicine in the management of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology. 2022. Т. 36, №1.
26. Wolfe F., Michaud K., Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum. 2004. Т. 50, №10. p.3296-305
27. Felson D.T., Smolen J.S.et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Care and Research, 2011. 63(3), p.573-586.
28. Gadallah M., Boulos D., Gebrel A., Dewedar S., Morisky D. Assessment of Rheumatoid Arthritis Patients' Adherence to Treatment. The American journal of the medical sciences. 2014. 349(2) p.151-156.
29. Yajima N., Kawaguchi T., Takahashi R. et al. Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: a multicenter cross-sectional study. BMC Rheumatol. 2022. 6, p.75
30. Jarab A.S., Al-Qerem W., Abu Heshmeh S.R., Alzoubi K.H., Mukattash T.L., Akour A. Disease control and its associated factors in outpatients with rheumatoid arthritis. Electron J Gen Med. 2023. 20(6). p.532-538
31. Siddique M.I. et al. Impact of Polypharmacy on Elderly Patients: A Comparative Study of Outcomes and Risk Management. Asian Journal of Pharmaceutics (AJP). 2024, 18(04). p.1054-1064.
Количество просмотров: 237
Категория статей:
Оригинальное исследование
Библиографическая ссылка
Petrova Y.V., IvanovaR.L., Goremykina M.V., Serikova T.K., Karakanova A.B., Bakytova A.B., Seitkhan D.S., Nogayeva M.G. Quality of life and adherence to therapy in patient with rheumatoid arthritis // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (1), pp. 40-48.doi 10.34689/SH.2024.27.1.005Похожие публикации:
VIRAL HEPATITIS IN KAZAKHSTAN: REGIONAL EPIDEMIOLOGICAL OVERVIEW
PREDICTORS OF ANTIVIRAL THERAPY INEFFECTIVENESS IN CHRONIC HEPATITIS C: A MATCHED CASE-CONTROL STUDY IN ALMATY, A MAJOR METROPOLIS OF KAZAKHSTAN
МЕДИКО – СОЦИАЛЬНЫЕ ОСОБЕННОСТИ ПРИВЕРЖЕННОСТИ К ЛЕЧЕНИЮ БОЛЬНЫХ С ХРОНИЧЕСКИМ ПАНКРЕАТИТОМ
PATHOGENETIC ASSESSMENT OF CLINICAL AND INSTRUMENTAL PARAMETERS OF THE LUNGS IN PATIENTS WITH DIABETES MELLITUS
ANTIBIOTIC RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VARIOUS CLINICAL BIOMATERIALS: A COMPARATIVE ANALYSIS